Ethris announces promising phase 1 results for ETH47, its mRNA therapy for uncontrolled asthma. The inhaled treatment showed strong safety and efficacy, with plans for a phase 2 trial in 2025.
Community-acquired pneumonia (CAP) is a systemic disease and continues to be the leading cause of infectious mortality ...
University of Kentucky Markey Cancer Center researchers have discovered a promising new way to combat therapy-resistant ...
As cases of respiratory viruses rise in Rhode Island, hospitals and medical facilities are starting to require patients to ...
Babies born during the COVID-19 pandemic had much lower risk for respiratory infections and antibiotic prescriptions during their first 18 months.
HealthDay News — In a clinical practice guideline issued by the American Thoracic Society and published in the January issue of the American Journal of Respiratory and Critical Care Medicine, updated ...
Enhance Management of Chronic Conditions: For children with chronic respiratory conditions, regular PEFR monitoring allows ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback